[Pharmaceutical therapy of breast cancer]

Magy Onkol. 2010 Sep;54(3):237-54. doi: 10.1556/MOnkol.54.2010.3.5.

[Article in Hungarian]

Authors

István Láng¹, Zsuzsanna Kahán, Tamás Pintér, Magdolna Dank, Katalin Boér, Gábor Pajkos, Zsolt Faluhelyi, Béla Pikó, Sándor Eckhardt, Zsolt Horváth

Affiliation

¹ Országos Onkológiai Intézet, Budapest.

PMID: 20870601
DOI: 10.1556/MOnkol.54.2010.3.5

No abstract available

Publication types

Practice Guideline

MeSH terms

Anemia / chemically induced
Anemia / therapy
Antineoplastic Agents, Hormonal / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biomarkers, Tumor / analysis*
Breast Neoplasms / chemistry
Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology
Cachexia / etiology
Cachexia / therapy
Chemotherapy, Adjuvant
Evidence-Based Medicine
Female
Humans
Male
Neoplasm Recurrence, Local / drug therapy
Neoplasm Staging
Neutropenia / chemically induced
Neutropenia / therapy
Receptor, ErbB-2 / analysis
Receptors, Estrogen / analysis
Receptors, Progesterone / analysis

Substances

Antineoplastic Agents, Hormonal
Biomarkers, Tumor
Receptors, Estrogen
Receptors, Progesterone
ERBB2 protein, human
Receptor, ErbB-2